Aptar Digital Health, a global digital health solutions provider, has on Wednesday announced that it has acquired Healint, a Singapore-based digital health company.

Aptar Digital Health said in a statement that the acquisition of Healint aligns with its strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment.

The expanded capabilities include patient community management, patient activation, artificial intelligence (AI) based data collection and analysis, as well as digital diagnostics to facilitate patient screening and identification.

Furthermore, Healint’s ability to conduct clinical studies at an accelerated pace and at a global scale complements Aptar Digital Health’s existing solutions to provide additional value to pharmaceutical customers.

“We are excited to welcome the Healint team and expand Aptar Digital Health’s product portfolio and capabilities to clinical trial management,

“With Healint, we now have the in-house expertise to cover the entire lifecycle of a drug, positioning Aptar Digital Health as a prominent leader in digital health for Central Nervous System conditions,” said Sai Shankar, President of Aptar Digital Health.

Meanwhile, Gael Touya, President of Aptar Pharma, commented that through this acquisition, the combined expertise of Aptar Digital Health and Healint in developing state-of-the-art solutions that empower patients in their disease journey fully aligns with Aptar Pharma’s primary ambition of improving patient experiences and health outcomes.

“The integration of Healint into Aptar Digital Health’s operations will commence immediately,

According to the statement, Aptar Digital Health will scale up Healint’s platform to adjacent therapeutic indications in neurology and immunology, and strengthen its current offering by adding new services such as clinical trial management tools.

“We are delighted to join the Aptar Digital Health team to better serve patients, healthcare professionals and pharmaceutical companies,

“This acquisition will accelerate the development of our AI-powered precision medicine SaMD designed to augment existing treatment, thanks to unique datasets and scientific expertise,” said François Cadiou, Chief Executive Officer and Founder of Healint.

Founded in 2013, Healint has been recognized for their virtual clinical studies, real-world evidence and patient registries platform, as well as the Migraine Buddy and Clarrio mobile apps, which support patients suffering from neurological and immunological conditions.

The firm is a pioneer in multimodal health and Quality of Life (QoL) tracking and clinically validated data collection, using self-input and sensor data at scale, interpreted via its proprietary AI.

It generates real-world evidence for patients, physicians and researchers to improve treatment outcomes and expedite clinical trials.

It has developed Migraine Buddy, the first patented migraine mobile app in the world, with over three million registered users.

Aptar Digital Health, on the other hand, is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies.

Aptar Digital Health is a global leader in digital health solutions (Software as a Medical Device [SaMD] and digital Patient Support Programs), connected devices and disease management.

The firm creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions.

Aptar Digital Health’s offering combines mobile and web apps, connected drug delivery systems, onboarding, training and advanced data analytics services to actively empower patients and create a positive treatment journey.

Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries.

Singapore’s Doctor Anywhere attracts $40.8M in fresh funding to scale healthcare innovation